Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLitigation Cap. Regulatory News (LIT)

Share Price Information for Litigation Cap. (LIT)

Share Price is delayed by 15 minutes
Get Live Data
2.60    -0.10 (-3.70%)
Bid:
2.50
Ask:
2.60
Spread: 0.10 (4.00%)
Market Cap: £2.68m
LIT Live PriceLast checked at - London Stock Exchange

Intraday Litigation Cap. Share Chart

Board Updates

2 Jul 2020 10:42

RNS Number : 8591R
Litigation Capital Management Ltd
02 July 2020
 

2 July 2020

 

Litigation Capital Management Limited

(LCM or the Company)

 

Board Updates

 

Litigation Capital Management Limited (AIM:LIT), specialist alternate asset manager and a leading international provider of disputes financing solutions, provides the following update:

 

· LCM currently looking to expand the geographic market reach of its Non-Executive Directors in line with LCM's business plan

· Steve McLean steps down as non-executive director as part of this upcoming Board realignment

· Minor delays in the CEO relocating to London due to COVID-19

 

LCM is at an advanced stage in the search to add additional Non-Executive Directors (NED) to the Board. As the Company strengthens its market positioning in the Northern Hemisphere, including the UK and Europe, as well as transitioning its management to the London office, it looks to new NED appointments to bring significant experience in these markets. As part of this upcoming restructuring, Steve McLean has kindly agreed to resign his position on the board effective as at 30 June 2020.

 

Steve was appointed to LCM's board as a NED prior to the Company's IPO on the Australian Securities Exchange. Steve brought with him significant in-region equity capital markets experience and has been a very valuable member of LCM's board during the building of its business, particularly in the APAC region.

 

LCM expects to be in a position to make an announcement as to a new Non-Executive board member in the near future.

 

Jonathan Moulds, Chairman of LCM, commented: "Steve has been a strong supporter of LCM through two IPOs, one on the Australian Securities Exchange and then on the London Stock Exchange:AIM as a Non-Executive board member. As LCM's business expands into new global markets, it will benefit from board experience in those large economies. We will continue to have access to Steve and his experience was a long-term supporter of the business. I thank him for his significant contribution to the growth of LCM over a number of years"

 

Enquiries

 

Litigation Capital Management

c/o Alma PR 

Patrick Moloney, Chief Executive Officer

 

 

 

Canaccord (Nomad and Joint Broker) 

Tel: 020 7523 8000

Bobbie Hilliam

 

 

 

Investec Bank plc (Joint Broker)

Tel: 020 7597 5970

David Anderson

 

 

 

Alma PR

Tel: 020 3405 0205

Rebecca Sanders-Hewett

LCM@almapr.co.uk

Justine James

 

David Ison

 

 

NOTES TO EDITORS

 

Litigation Capital Management (LCM) is a global provider of disputes finance which operates two business models. The first is direct investments made from LCM's permanent balance sheet capital and the second is fund and/or asset management. Under those two business models, LCM currently pursues three investment strategies: Single-case funding, Corporate portfolio funding and Acquisitions of claims. LCM generates its revenue from both its direct investments and also performance fees through asset management.

LCM has an unparalleled track record, driven by effective project selection, active project management and robust risk management.

 

Headquartered in Sydney, with offices in London, Singapore, Brisbane and Melbourne, LCM listed on AIM in December 2018, trading under the ticker LIT.

 

www.lcmfinance.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOASSUSUEESSEDW
Date   Source Headline
8th Jul 20227:00 amRNSMarket Update
16th May 20227:00 amRNSLitigation Finance Agreement
4th May 202210:15 amRNSDirector/PDMR Shareholding
25th Apr 20229:30 amRNSDirector/PDMR Shareholding
11th Apr 202211:10 amRNSDirector/PDMR Shareholding
15th Mar 20227:00 amRNSInterim Results
14th Mar 202210:30 amRNSHolding(s) in Company
15th Feb 20227:00 amRNSNotice of Results
14th Feb 20227:00 amRNSMary Gangemi Appointed to the Board
7th Feb 202210:30 amRNSDirector/PDMR Shareholding
1st Feb 202212:45 pmRNSDirector/PDMR Shareholding
4th Jan 20223:58 pmRNSHolding(s) in Company
29th Dec 20214:10 pmRNSDirector/PDMR Shareholding
17th Dec 20217:00 amRNSBoard change
10th Dec 202112:30 pmRNSIssue of Equity and Total Voting Rights
18th Nov 20217:00 amRNSResult of AGM
4th Nov 20217:00 amRNSSuccessful Award in LCIA International Arbitration
29th Oct 20211:24 pmRNSExercise of Options, Equity Issue, Director/PDMR
29th Oct 20211:00 pmRNSIncentive Awards
25th Oct 20217:00 amRNSNotice of AGM
18th Oct 202111:15 amRNSIssue of Equity and Total Voting Rights
14th Oct 20217:00 amRNSLCM Global Alternative Returns Fund II
22nd Sep 202111:20 amRNSHolding(s) in Company
21st Sep 20217:00 amRNSFinal Results 2021
31st Aug 20217:00 amRNSNotice of Results
11th Aug 20217:07 amRNSSuccessful judgment in Australian investment
19th Jul 20217:00 amRNSMarket Update
6th Jul 20217:00 amRNSNew Litigation Finance Agreement
23rd Jun 20217:00 amRNSComet Group liquidation claim
21st Jun 20217:21 amRNSJudgment in New Zealand Investment
27th May 20217:00 amRNSInvestor Presentation
19th May 20217:18 amRNSLitigation Finance Agreement with Carillion
4th May 202112:09 pmRNSHolding(s) in Company
14th Apr 20214:41 pmRNSSecond Price Monitoring Extn
14th Apr 20214:36 pmRNSPrice Monitoring Extension
16th Mar 20217:00 amRNSInterim Results
10th Mar 20216:07 pmRNSIssue of Equity and Total Voting Rights
10th Mar 20215:53 pmRNSHolding(s) in Company
25th Feb 20217:00 amRNSRetail Investor Presentation
22nd Feb 20217:00 amRNSNew US$50m Credit Facility
18th Feb 20212:30 pmRNSHolding(s) in Company
17th Feb 20217:00 amRNSNotice of Results
12th Feb 20215:13 pmRNSHolding(s) in Company
7th Jan 202111:20 amRNSHolding(s) in Company
17th Dec 202012:17 pmRNSHolding(s) in Company
19th Nov 20207:00 amRNSResult of AGM
28th Oct 20207:00 amRNSNotice of Annual General Meeting
15th Oct 202010:30 amRNSIncentive Awards
15th Oct 20207:00 amRNSHolding(s) in Company
23rd Sep 20204:26 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.